Is Immunocore Holdings (IMCR) Undervalued After Stronger Revenue And Profitability Results?

Simply Wall St.08-18

Immunocore Holdings (IMCR) reported its second quarter and six month results on August 6, 2026, with higher revenue and a move from a net loss to net income over the half year period. See our latest ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660437147?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-18 05:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660437147","market":"sg","top_or_hot":-1,"title":"Is Immunocore Holdings (IMCR) Undervalued After Stronger Revenue And Profitability Results?","media":"Simply Wall St.","content":"<div>\n<p>Immunocore Holdings (IMCR) reported its second quarter and six month results on August 6, 2026, with higher revenue and a move from a net loss to net income over the half year period. See our latest ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/is-immunocore-holdings-imcr-undervalued-after-stronger-reven\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Immunocore Holdings (IMCR) Undervalued After Stronger Revenue And Profitability Results?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Immunocore Holdings (IMCR) Undervalued After Stronger Revenue And Profitability Results?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-18 05:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/is-immunocore-holdings-imcr-undervalued-after-stronger-reven><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immunocore Holdings (IMCR) reported its second quarter and six month results on August 6, 2026, with higher revenue and a move from a net loss to net income over the half year period. See our latest ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/is-immunocore-holdings-imcr-undervalued-after-stronger-reven\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMCR","symbol_name":"Immunocore Holdings plc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/is-immunocore-holdings-imcr-undervalued-after-stronger-reven","article_id":"2660437147","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imcr/immunocore-holdings/news/is-immunocore-holdings-imcr-undervalued-after-stronger-reven","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660437147","pubTimestamp":1787001921,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Immunocore Holdings (IMCR) reported its second quarter and six month results on August 6, 2026, with higher revenue and a move from a net loss to net income over the half year period.\nSee our latest analysis for Immunocore Holdings.\nAt a share price of US$34.21, Immunocore Holdings shows a 90 day share price return of 18.25%, while the 1 year total shareholder return of 5.88% contrasts with a 3 year total shareholder return that is down 42.85%. This suggests that momentum has been rebuilding...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IMCR":"Immunocore Holdings plc"},"translate_title":"Immunocore Holdings (IMCR) 在收入和盈利能力增强后是否被低估？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMCR":1.5},"content_text":"Immunocore Holdings (IMCR) reported its second quarter and six month results on August 6, 2026, with higher revenue and a move from a net loss to net income over the half year period. See our latest analysis for Immunocore Holdings. At a share price of US$34.21, Immunocore Holdings shows a 90 day share price return of 18.25%, while the 1 year total shareholder return of 5.88% contrasts with a 3 year total shareholder return that is down 42.85%. This suggests that momentum has been rebuilding more recently following the stronger first half results. If Immunocore Holdings has your attention after these earnings, it can be helpful to see how other healthcare companies exposed to artificial intelligence are trading right now through 41 healthcare AI stocks Immunocore Holdings has moved back into profit, while the share price still sits well below many intrinsic value estimates. The gap between that US$34.21 price and fair value assumptions is what really matters next. AdvertisementMost Popular Narrative: 48.6% Undervalued Immunocore Holdings is trading at US$34.21 against a most-followed narrative fair value of US$66.57, which frames the current share price as a steep discount.  Significant cash balance ($883 million) and disciplined SG&A spend provide Immunocore with the resources and strategic flexibility to advance its clinical portfolio and capitalize on long-term industry trends, supporting revenue growth and potential positive net margins in the future.  Read the complete narrative. To see how this cash position, projected revenue build and anticipated margin profile are incorporated into that higher fair value, review the full narrative for the detailed connections. Result: Fair Value of $66.57 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Immunocore Holdings still faces key risks, including heavy reliance on KIMMTRAK and rising R&D spending that could pressure margins if trial outcomes or reimbursement terms disappoint. Find out about the key risks to this Immunocore Holdings narrative. Another View on Immunocore Holdings Valuation The most followed narrative suggests Immunocore Holdings is heavily undervalued at US$34.21 compared with a fair value of US$66.57. Yet its P/S ratio of 4.1x sits well below the US Biotechs industry at 10.9x and the peer average of 16.6x, while sitting above a fair ratio of 3.5x. That mix of a low current P/S against industry and peers, but a premium to the fair ratio, hints at both potential opportunity and valuation risk if sentiment or revenue expectations change. The key question is which reference point investors will lean on next: the market or the fair ratio. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:IMCR P/S Ratio as at Aug 2026Next Steps Given the mixed messages from Immunocore Holdings' valuation and narrative signals, it makes sense to move quickly and test the numbers yourself. To see what is driving the optimism and which rewards stand out most clearly, review the 3 key rewards Looking for more investment ideas beyond Immunocore Holdings? You have seen how Immunocore Holdings stacks up. Now broaden your watchlist with fresh ideas that could sharpen your overall portfolio positioning.  Target income resilience by reviewing companies identified as potential 10 dividend fortresses that may help support more reliable cash flows from dividends. Hunt for mispriced quality by using the screener of screener containing 19 high quality undiscovered gems that many investors may not be watching closely yet. Strengthen downside protection by focusing on the 80 resilient stocks with low risk scores and see which stocks score well on risk factors that matter to you.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660437147","isCrawlerRequest":true}